Joshua Jennings
Stock Analyst at TD Cowen
(3.14)
# 1,013
Out of 4,814 analysts
68
Total ratings
41.27%
Success rate
1.66%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVR Anteris Technologies Global | Initiates: Buy | $15 | $2.88 | +421.74% | 1 | Jan 7, 2025 | |
| PODD Insulet | Maintains: Buy | $264 → $324 | $246.95 | +31.20% | 1 | Jan 3, 2025 | |
| BSX Boston Scientific | Maintains: Buy | $100 → $110 | $95.25 | +15.49% | 7 | Dec 12, 2024 | |
| CBLL CeriBell | Maintains: Buy | $31 → $36 | $14.86 | +142.26% | 2 | Dec 9, 2024 | |
| TMDX TransMedics Group | Maintains: Buy | $175 → $120 | $88.24 | +35.99% | 9 | Nov 18, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $1.66 | +502.41% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $50 | $2.35 | +2,027.66% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $53.04 | +86.65% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $97.88 | +21.58% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $41.19 | +45.68% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $83 → $80 | $81.16 | -1.43% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $45 | $11.06 | +306.87% | 3 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $100 → $70 | $71.56 | -2.17% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $185 | $157.44 | +17.51% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $28.89 | +38.46% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $346.60 | +15.41% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $31.58 | +89.99% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $16.86 | +101.72% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $4.87 | +269.61% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $68.61 | +82.19% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $17.09 | +46.28% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $129.70 | +0.23% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.83 | +173.22% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $82.70 | +41.48% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $5.44 | +8,172.06% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $10.54 | +13.91% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $200.40 | +37.23% | 1 | Feb 7, 2020 |
Anteris Technologies Global
Jan 7, 2025
Initiates: Buy
Price Target: $15
Current: $2.88
Upside: +421.74%
Insulet
Jan 3, 2025
Maintains: Buy
Price Target: $264 → $324
Current: $246.95
Upside: +31.20%
Boston Scientific
Dec 12, 2024
Maintains: Buy
Price Target: $100 → $110
Current: $95.25
Upside: +15.49%
CeriBell
Dec 9, 2024
Maintains: Buy
Price Target: $31 → $36
Current: $14.86
Upside: +142.26%
TransMedics Group
Nov 18, 2024
Maintains: Buy
Price Target: $175 → $120
Current: $88.24
Upside: +35.99%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $1.66
Upside: +502.41%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $50
Current: $2.35
Upside: +2,027.66%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $53.04
Upside: +86.65%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $97.88
Upside: +21.58%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $41.19
Upside: +45.68%
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $81.16
Upside: -1.43%
Aug 8, 2024
Maintains: Buy
Price Target: $135 → $45
Current: $11.06
Upside: +306.87%
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $71.56
Upside: -2.17%
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $157.44
Upside: +17.51%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $28.89
Upside: +38.46%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $346.60
Upside: +15.41%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $31.58
Upside: +89.99%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $16.86
Upside: +101.72%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $4.87
Upside: +269.61%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $68.61
Upside: +82.19%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $17.09
Upside: +46.28%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $129.70
Upside: +0.23%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.83
Upside: +173.22%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $82.70
Upside: +41.48%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $5.44
Upside: +8,172.06%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $10.54
Upside: +13.91%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $200.40
Upside: +37.23%